Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308743 | 0.93 | ALDH1A1 (0.35) | ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL18308793 | 0.91 | ALDH1A1 (0.34) | HSD17B1HSD17B2ALDH1A1CYP3A4TSHR | |
| SCHEMBL18308808 | 0.87 | HSD17B1 (0.38) | HSD17B1HSD17B2ESR2ALDH1A1CYP3A4 | |
| SCHEMBL18308770 | 0.85 | ESR1 (0.34) | ESR2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL18308771 | 0.85 | ESR1 (0.34) | ESR2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL18308731 | 0.83 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL18308777 | 0.83 | HSD17B1 (0.39) | HSD17B1HSD17B2ESR2CYP3A4MEN1 | |
| SCHEMBL18308750 | 0.82 | ALDH1A1 (0.35) | HSD17B1HSD17B2ALDH1A1CYP3A4TSHR | |
| SCHEMBL18806018 | 0.81 | HSD17B1 (0.34) | HSD17B1HSD17B2ESR2ALDH1A1CYP3A4 | |
| SCHEMBL18308801 | 0.78 | HSD17B1 (0.43) | HSD17B1HSD17B2ESR2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-08 | — | — | US | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | VCL, ILK, LCP1 | HSD17B1 4322/4885HSD17B2 4127/4885ESR2 4146/4885 |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, LCP1, MAP1LC3C | HSD17B1 4477/4885HSD17B2 4441/4885ESR2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.